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ABSTRACT 49 
Objective To examine the microRNA (miRNA) expression pattern in tumour samples 50 
of progressing and non-progressing upper tract urothelial carcinoma (UTUC) patients in 51 
order to identify putative miRNAs that may be used as prognostic markers.  52 
Subjects and methods Multicenter, retrospective study of formalin-fixed paraffin 53 
embedded tissue samples from 150 UTUC patients who underwent radical 54 
nephroureterectomy. Global miRNA expression patterns were analyzed in 18 selected 55 
samples from UTUC patients using TaqMan arrays. Differential expression of five key 56 
miRNAs was validated by quantitative PCR in an independent cohort of 132 samples 57 
from UTUC patients.  Tumour progression and cancer-specific survival predicting 58 
models, including miRNA expression patterns, were developed by Cox regression 59 
analysis. 60 
Results Twenty-six miRNAs were found to be aberrantly expressed between 61 
progressing and non-progressing UTUC patients and five of these were selected for 62 A
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subsequent studies. The regression analysis identified tumour stage and miR-31 and 63 
miR-149 expression as independently associated with tumour progression and tumour 64 
stage and miR-149 expression as independently associated with cancer-specific 65 
survival. 66 
The risk scores (RS) derived from these miRNAs models were able to discriminate two 67 
groups with a highly significant different probability of tumour progression (HR 4,78; 68 
p<0.001) and death (HR 2.76; p=0.0036). 69 
Conclusion There is a differential miRNA expression pattern between progressing and 70 
non-progressing UTUC patients. Identification of new miRNAs associated with a high 71 
probability of tumour recurrence and cancer-specific survival in UTUC patients and 72 
their combination in a robust, easy-to-use and reliable algorithm may contribute to tailor 73 
treatment and surveillance strategies in these patients. 74 
 75 
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INTRODUCTION 78 
Radical nephroureterectomy (RNU) is the gold-standard treatment for localized upper 79 
tract urothelial carcinoma (UTUC) [1]. There are only a few established prognostic 80 
factors associated with tumour progression and survival, notably pathological stage 81 
and tumour grade, but these are insufficient to predict the individual outcome of UTUC 82 
patients [2]. Predictive tools such as nomograms have been proposed after RNU but 83 
they are still lacking high accuracy [3]. Thus, more accurate knowledge regarding the 84 
biological behaviour of tumours would allow tailored treatment schedules to be offered 85 
to patients, in an attempt to increase survival and decrease morbidity. 86 
The rapid advance in the understanding of the molecular biology of carcinogenetic 87 
processes has lead to the appearance of promising new cancer biomarkers such as 88 
microRNAs (miRNAs). miRNAs are a class of small non-coding RNAs that regulate 89 
various biological processes post-transcriptionally and are dysregulated in most 90 
cancer types [4-7]. However, to our knowledge, the complete miRNA profiling of 91 
UTUC patients has not yet been explored. Unlike mRNA, miRNAs have been shown 92 
to be unusually well-preserved in a range of specimens, including formalin-fixed 93 
paraffin embedded tissue samples [8]. This stability offers a distinct advantage of 94 
miRNA over mRNA as the analyte in the clinical setting, and has led to a 95 
considerable interest in the development of miRNAs as biomarkers for molecular 96 
diagnostic, prognostic and therapeutic applications. 97 
Here, we aimed to examine, for the first time, the miRNA expression profiles of 98 
progression and non-progression UTUC patients in order to identify putative miRNAs 99 
that may be used as prognostic markers.  100 
 101 
 102 
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PATIENTS AND METHODS 104 
Patients 105 
A retrospective study in which a total of 150 patients (mean age 70 yr, range 45-101 yr; 106 
34 females, 116 males) with UTUC who underwent nephroureterectomy in three 107 
different centers (Hospital Clinic of Barcelona-Spain, Pitié Salpétrière Hôspital of Paris-108 
France and Claude Huriez Hôspital of Lille-France) between 1990 and 2004 were 109 
included. The only exclusion criterion was the lack of tissue from the archive blocks. 110 
Pathological characteristics of the UTUC patients are shown in table 1. Tumours were 111 
graded and classified according to the WHO’s [9] and the TNM’s classification of the 112 
International Union Against Cancer [10]. Tissue samples were obtained under 113 
institutional review board-approved protocol.  114 
The median follow-up of the studied population was 46 months (range 3-213 mo). All 115 
patients were followed-up postoperatively in three-month intervals for the first year, in 116 
6-month intervals for the next two years, and annually thereafter. Tumour was 117 
considered to be in progression when distant metastasis or pathological nodes were 118 
developed during the follow-up. 119 
Tissue specimens and RNA isolation 120 
Upon obtainment the tissue was fixed in 10% formalin within 24 h and subsequent 121 
embedded in paraffin. A slide of each specimen was stained with haematoxylin-eosin 122 
to determine the presence of tumour cells. Only those specimens with a minimum of 123 
75% of tumour cells were considered for further analysis. Total RNA was isolated from 124 
specimens (80-m) using the RecoverAll Total Nucleic Acid Isolation Kit (Ambion INC) 125 
according to the manufacturer’s protocol. Total RNA was quantified by 126 
spectrophotometric analysis at 260 nm (NanoDrop Technologies, Wilmington, DE, 127 
USA). 128 
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Global screening phase 130 
A flowchart of the entire study in shown in Figure 1. Global miRNA profiling of 18 131 
randomly selected UTUC cases from Hospital Clinic of Barcelona, nine progressing 132 
(pTa=1, pT1=1, pT2=1, pT3=4, pT4=2; G1=7, G2=1, G3=1; mean progression= 17.2 133 
months) and nine non-progressing (pTa=1, pT1=6, pT2=1, pT3=1; G2=6, G3=3; mean 134 
follow-up= 94 months), was performed using TaqMan® Array Human MicroRNA A+B 135 
Cards Set v2.0 (TA) that contain 754 unique assays specific to human miRNAs and 136 
four control assays in each card (Applied Biosystems, Foster City, USA, hereafter 137 
referred to as AB) according to manufacturer’s instructions. Briefly, miRNAs were 138 
reverse transcribed with the TaqMan MicroRNA Reverse Transcription kit (AB) using 139 
500 ng of total RNA following manufacturer’s instructions (Megaplex RT primers for 140 
Human Pool A and B, AB). After reverse transcription, 2.5 μl of cDNA was preamplified 141 
with Megaplex PreAmp primers following manufacturer’s instructions (AB), except that 142 
the final volume of the reaction was 25 μl instead of 50 μl. Then, an aliquot of 1 μl of 143 
preamplified cDNA was applied to verify the actual amount of RNU48 using the specific 144 
primer/probe set (AB) via quantitative PCR (qPCR). Standard reaction and 145 
amplification conditions were used (final volume of qPCR reaction of 10 μl). Those 146 
samples that provided cycle quantification (Cq) value for the RNU48 lower than 17-18 147 
were diluted with water to ensure a homogeneous amount of cDNA in all samples and 148 
the correct quantification of the miRNAs. Afterwards, miRNAs were analyzed in TA 149 
using an ABI7900HT instrument. 150 
Technical validation of differentially expressed miRNAs 151 
To select miRNAs for technical validation using a different methodology, we 152 
used the false discovery rate (FDR) ≤10% and absolute fold change (FC) ≥ 2 153 
between distinct groups in TaqMan® Human MicroRNA Array (n=21). Then, we 154 
checked whether these differentially expressed miRNAs belonged to the same 155 
miRNA cluster and only one miRNA from each was then selected for further 156 A
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validations (For example clusters hsa-miR-200a, hsa-miR-200b, hsa-miR-200a*, 157 
hsa-miR-200b* or hsa-miR-141, hsa-miR-200c, hsa-miR-141* containing several 158 
differentially expressed miRNAs from our list). Finally, a total of eight differentially 159 
expressed miRNAs obtained in TA were selected for validation in the 18 previously 160 
analyzed samples, using miRCURY LNA Universal RT microRNA PCR kit (Exiqon, 161 
Vedbaek, Denmark). 162 
RT-qPCR reactions were performed according to the manufacturers’ instructions 163 
(Exiqon, Vedbaek, Denmark). Briefly, cDNA was synthesized using a poly(T) primer 164 
and was amplified with locked nucleic acid (LNA) primers and SYBR Green master 165 
mix. Specific LNA PCR primer sets used were hsa-miR-200a, hsa-miR-31, hsa-miR-166 
493, hsa-miR-99a, hsa-miR-378*, hsa-miR-181a-2*, hsa-miR-149 and hsa-miR-141. 167 
hsa-miR-218 was used as an endogenous control. PCR reactions were carried out 168 
using standard conditions in an ABI7900HT instrument. At the end of the PCR cycles, 169 
melting curve analyses were performed.  170 
Classifier discovery phase 171 
A total of five key miRNAs (miR-31, miR-493, miR-99a, miR-181a-2* and miR-149) 172 
were selected for validation in an independent series of 132 tissue samples; 56 from 173 
Claude Huriez Hospital of Lille, 16 from Pitié Salpétrière Hospital of Paris and 60 from 174 
Hospital Clinic of Barcelona. miR-493, miR-99a and miR-181a-2* were selected 175 
because we found that they were differentially expressed (p<0.05) between both 176 
groups via two different techniques in the same cohort of patients (Table 2). 177 
Moreover, we also decided to further analyze miR-31 and miR-149 expression in 178 
the independent cohort because, although their expression was not statistically 179 
significant between both groups in the technical validation step, they had an 180 
absolute FC ≥2 and their differential expression was in the same direction using 181 
both RT-qPCR based techniques. It should be taken into account that the initial 182 
cohort of patients was small (n=18), so statistically significant differences should 183 A
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be analysed with care and furthermore, we were searching for biomarkers 184 
predictors of tumour progression and cancer-specific survival, and it has been 185 
previously reported that not significance but discrimination is important for a 186 
biomarker [11]. 187 
RT-qPCR reactions were performed using miRCURY LNA kit as described above 188 
Data analysis 189 
TaqMan® Human MicroRNA Array: RT-qPCR data was processed with SDS 2.4 and 190 
Enterprise software packages (AB). An automatic threshold and baseline was used for 191 
all the miRNAs to record the Cq value. Data normalization was carried out using a 192 
global mean normalization method [12]. Subsequently, miRNAs with expression levels 193 
correlating to the global mean Cq values were identified and miR-218 was selected by 194 
using GeNorm as reference miRNA [13]. 195 
Those miRNAs with Cq values above 35 in at least 45% of samples were filtered out, 196 
giving a total of 409 valid miRNAs. Relative expression levels of target miRNAs within a 197 
sample was expressed as Cq (Cq= CqmiR-218-Cqtarget miRNA). miRNAs with Cq values 198 
above 35 were considered as lowly expressed, and their Cq were imputed to 199 
minimum Cq value for that miRNA. Fold change values were generated from the 200 
median expression of the miRNAs from the TaqMan® Human MicroRNA Array in the 201 
groups compared. Differences in miRNA expression levels between progressing and 202 
non-progressing patients were explored using the Student’s t test. Significance was 203 
defined as False Discovery Rate (FDR) values of less than 10%. R-software was used 204 
for all calculations and to construct heatmap. 205 
microRNA LNATM real-time RT-qPCR: No miRNAs with Cq values above 35 were found 206 
when using LNA primers. Samples with a miR-218 Cq value higher than 30 were 207 
considered to have low RNA quality and were excluded from the analysis. Cq values 208 
were calculated as described above. 209 A
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Statistical analysis 210 
Univariate Cox regression analysis was performed on each covariate to examine its 211 
influence on tumour progression and cancer–specific survival. Thereafter, a 212 
multivariate forward stepwise Cox regression analysis was performed. Statistical 213 
significance was established at α-value of 0.05. SPSS 12.0 software was used for 214 
statistical analysis. 215 
After establishing the multivariate model, a risk score (RS) for the miRNAs of the model 216 
was calculated for each patient according to the general form RS= exp Σβixis, where i 217 
= 1, . . ., k index variables, βi represents the coefficient for each variable estimated 218 
from the Cox regression model, and xis the corresponding value for each variable in a 219 
given patient. RS was subjected to a ROC analysis in order to choose the most 220 
appropriate threshold for predicting tumour progression and cancer-specific survival. 221 
Thereafter, Kaplan-Meier curves were generated using the selected cut-off point and 222 
compared according to the log-rank test. Since progression and time of death was not 223 
available for three patients, survival analyses were performed using the 147 available 224 
patients. 225 
Pathway enrichment analysis 226 
DIANA-mirPath tool [14], using TargetScan as the target prediction algorithm, was 227 
used to identify targets of the key miRNAs, and subsequent target enrichment analysis 228 
was performed in order to discover possible canonical altered pathways. 229 
 230 
RESULTS 231 
Global screening phase 232 
Overall, analysis of TaqMan® Human MicroRNA Array-derived expression data from 233 
nine progression and nine non-progression cases resulted in the identification of 26 234 
miRNAs with a FDR of less than 10%; 20 downregulated and six upregulated miRNAs 235 A
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in deceased with respect to live patients. Heat map based on differentially expressed 236 
miRNAs shows a distinction between progression and non-progression group (Figure 237 
2).  238 
Technical validation of differentially expressed miRNAs  239 
To assure the consistency in the experimental procedures followed in the screening 240 
phase, we used a different approach, based on LNATM PCR primer sets, to quantify 241 
eight selected miRNAs in the same 18 samples evaluated using the TaqMan® Human 242 
MicroRNA Array. Even though there are several methodological differences between 243 
both platforms, six of the eight miRNAs tested maintained the same fold change 244 
direction when analyzed with LNATM PCR primer sets and in three of them (miR-181a-245 
2*, miR-493 and miR-99a), these differences were statistically significant (p<0.05) 246 
(Table 2).  247 
miRNAs associated with tumour progression and cancer-specific survival 248 
In order to identify miRNAs correlated with patient’s progression and survival, 249 
expression levels of five key miRNA, were analyzed by RT-qPCR in an independent 250 
cohort of 132 UTUC tissue samples. During the follow-up period of these 132 patients, 251 
39 (26%) developed tumour progression and 37 (24.7%) died due to UTUC. Five-year 252 
tumour progression and cancer-specific survival of the series were 71.67% and 253 
70.13%, respectively. The mean time to tumour progression and death were 15.91 and 254 
30.81 months, respectively.  255 
To verify whether these five selected miRNAs were independent prognostic factors of 256 
patient’s progression and survival, the miRNAs and the clinical variables in all 132 257 
patients were analyzed by Cox regression model. First, the univariate analysis revealed 258 
significant predictors of tumour progression and cancer-specific survival (Table 3). 259 
Then, the multivariate regression analysis demonstrated that pathological tumour stage 260 
and expression of miR-31 and miR-149 were independent prognostic factors of tumour 261 A
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progression (HR 2.46; p<0.001, HR 0.88; p<0.001 and HR 0.78; p=0.006, respectively) 262 
and pathological tumour stage and miR-149 expression were independent prognostic 263 
factors of cancer-specific survival (HR 1.79; p=0.0001 and HR 0.82; p=0.0183, 264 
respectively). 265 
The RS for tumour progression was calculated for each patient according to a 266 
mathematical algorithm containing miR-31 and miR-149 expression values. The 267 
median value of this RS was 0.574 (range 0.043-10.98). Thereafter, a ROC analysis of 268 
the model allowed selecting a cut-off value of 0.86 to classify patients into a high-risk 269 
group of tumour progression (27%) and low-risk group of tumour progression (73%). 270 
Figure 3A depicts Kaplan-Meier curves generated using the selected cut-off point. As 271 
shown, RS generated using miRNA expression values was able to discriminate two 272 
groups with a highly significant different probability of tumour progression (HR 4.78; 273 
p<0.001). 274 
In parallel, the RS for cancer-specific survival was calculated using miR-149 275 
expression values (RS median value=0.784; range 0.188-2.431). The subsequent ROC 276 
analysis allowed selecting a cut-off value of 0.93 to classify patients into a high-risk 277 
group of cancer-specific survival (35%) and low-risk group of cancer-specific survival 278 
(65%). The RS generated was able to discriminate two groups with a significantly 279 
different probability of cancer-specific survival (HR 2.76; p=0.0036) ( Figure 3B). 280 
 281 
DISCUSSION 282 
Around 30% of UTUC patients analyzed in this study died due to their tumour after 5-283 
years follow-up. Pathological stage and histological grade are the established 284 
prognostic factors for UTUC but they are insufficient to predict individual tumour 285 
behaviour. Thus, it would be of interest to find more reliable and individualized 286 
prognostic markers. To this end, different molecular markers have been previously 287 A
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evaluated in samples from UTUC patients by using immunohistochemistry (IHC) [15-288 
21] or in situ hybridization [22], however, none of them have been incorporated into the 289 
clinical setting. We have also previously analyzed gene expression patterns of several 290 
genes in UTUC samples but we were not able to identify prognostic factors of UTUC 291 
based on the genes analyzed [15]. 292 
miRNAs have been described as novel prognostic molecules involved in several 293 
tumours [4-7]. However, to our knowledge, miRNA expression profiles of progression 294 
and non-progression UTUC patients had not been explored as yet. In the current study, 295 
we first investigated global miRNA expression patterns in tissue samples from a 296 
reduced cohort of UTUC patients. Here we identified a list of 26 miRNAs differentially 297 
expressed between progressing and non-progressing UTUC patients. However, we 298 
were aware that although global miRNA expression profiling of UTUC samples 299 
provides miRNAs implied in UTUC progression, it represents early data that needs 300 
further validation. To this end, we first selected eight differentially expressed miRNAs to 301 
be validated in the same cohort using a different real time PCR-based approach. Five 302 
of the eight miRNAs were technically validated indicating that although both 303 
approaches used in this study are real time PCR-based, methodological differences 304 
between both qPCR platforms such as the priming system for reverse transcription, the 305 
employment of a preliminary cDNA preamplification step and the chemistry used in the 306 
qPCR reaction could result in some discrepancies. In fact, the partial validation of 307 
global profiling studies by RT-qPCR as well as differences in the magnitude of change 308 
have been previously reported [23]. 309 
Finally, in order to identify miRNAs that correlate with tumour progression and shorter 310 
survival, we tested these five miRNAs in an independent, larger, multicentre cohort of 311 
UTUC patients. As shown, tumour stage and miR-31 and miR-149 expression 312 
independently predict tumour progression and moreover, tumour stage and miR-149 313 
expression independently predicts cancer–specific survival. As a result, the RS derived 314 A
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from miRNAs in our multivariate model was able to discriminate two groups with a 315 
highly significant different probability of tumour progression (HR=4.78; p<0.001) and 316 
cancer–specific survival (HR=2.76; p=0.0036). Thus, a model composed of miR-31 and 317 
miR-149 provides a robust, easy-to-use system to identify a subgroup of patients with a 318 
higher probability of tumour progression, while expression of miR-149 is able to identify 319 
a subgroup of patients with shorter survival. Thus, the analysis of these two miRNAs in 320 
UTUC tissue samples refines the currently used clinico-pathological-based approach 321 
by adding the analysis of a limited number of genetic markers which could be very 322 
useful for making decisions in clinical practice.  323 
Regarding the genetic markers included in our algorithm, miR-149 has been found to 324 
be dysregulated in many tumours including clear renal cell carcinoma, squamous cell 325 
carcinoma of the tongue, prostate cancer, glioblastoma and astrocytoma. In addition, it 326 
has been described to serve as a diagnostic and prognostic marker for bladder and 327 
colorectal cancer [24,25]. On the other hand, miR-31 expression has been found 328 
altered not only in bladder cancer but also in prostate, gastric, breast and serous 329 
ovarian cancer [26], but functional roles for miRNA-31 have yet to be defined.  330 
Several possible pathways were predicted to be modified by the key miRNAs miR-31 331 
and miR-149. The statistically significant altered pathways in tumour progression and 332 
cancer-specific survival are shown in Table 4. Notably, some of these altered pathways 333 
predicted by these two miRNAs have been previously associated with other cancers, 334 
specially hematologic and breast neoplasms [27,28]. 335 
Regarding the application of miRNAs in the clinical setting, it is of interest to consider 336 
that miRNAs have some methodological advantages over gene expression studies. 337 
First, it is harder to obtain high quality long-chain mRNA from tissue samples. On the 338 
other hand, short mature miRNAs are more stable against nuclease degradation due to 339 
their smaller size and actually, the isolation of high quality miRNA from FFPE blocks 340 
has already been reported [8], suggesting that miRNAs may escape the chemical 341 A
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degradation induced by formalin fixation. Also, the average copy number of an 342 
individual miRNA species has been estimated at approximately 500 per cell, which may 343 
be higher than the average expression of mRNA species [29]. This implies that less 344 
total RNA is required for a miRNA than for an mRNA expression experiment, which is 345 
an important advantage when working with clinical samples. 346 
The strength of this study relies on the fact that we have used a nontargeted, 347 
exploratory approach to select the candidate miRNAs. Furthermore, we have used 348 
archival FFPE samples to obtain miRNA expression patterns allowing an easy 349 
translation of the results obtained to clinical practice. Finally, a multicenter cohort with 350 
prospective data collection and long term follow-up is analyzed in the present study, 351 
which eliminates the limitations of a single population study. We are aware, however, of 352 
some limitations of the study. First, we chose a group of eight miRNAs to validate from 353 
the initial study where 26 differentially expressed miRNAs were shown. It remains 354 
possible that we may have ruled out some miRNAs highly predictors of tumour 355 
progression and cancer-specific survival. Second, although we have tried to include a 356 
substantial number of patients from three different centres, the total number of patients 357 
analyzed can still be considered as low. Moreover, because of our interest in identifying 358 
robust markers, all available patients were used to discover prognostic miRNAs, thus 359 
preventing an independent validation. In that sense, although the data reported 360 
warrants further prospective evaluation in carefully and specifically designed studies, 361 
our study may contribute to the identification of a reliable prognostic system for UTUC 362 
patients. 363 
In conclusion, our results demonstrate that there is a differential miRNA expression 364 
pattern between non-progressing and progressing UTUC patients. We also show that 365 
an algorithm that combines miR-31 and miR-149 expression is able discriminate two 366 
groups associated with different probability of tumour progression. Furthermore, miR-367 
149 expression was able to distinguish two groups with different cancer-specific 368 A
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survival. Although independent validation of the data is necessary, identification of new 369 
miRNAs associated with a high probability of tumour recurrence and cancer-specific 370 
survival in UTUC patients and its combination in a robust, easy-to-use and reliable 371 
algorithm may contribute to tailor treatment and surveillance strategies in these 372 
patients. 373 
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LEGENDS TO ILLUSTRATIONS 468 
Figure 1. Study outline. Tissue samples were obtained from a total of 150 UTUC 469 
patients. Samples were divided into a screening (18 samples) and discovery phase 470 
(132 samples). miRNAs differentially expressed between progressing and non-471 
progressing UTUC patients were first identified in the screening phase using the 472 
TaqMan® Human MicroRNA Array. Eight of the miRNAs with false discovery rate 473 
(FDR) ≤10% and absolute fold change (FC) ≥ 2 between distinct groups were 474 
selected for technical validation in the same cohort using a different platform. 475 
This was followed by a search to identify genetic UTUC prognostic markers by 476 
analyzing five miRNAs that had gave p<0.05 or/and absolute FC ≥ 2 between 477 
distinct groups in the results from the technical validation.  None of the samples 478 
from the screening set were employed for the genetic markers discovery process.  479 
 480 
Figure 2. miRNAs differentially expressed between progressing and non 481 
progressing UTUC patients. (A) Heat map displaying the 26 miRNAs differentially 482 
expressed (FDR<10) between progressing and non-progressing UTUC patients in the 483 
TaqMan® Human MicroRNA Array (n=18). Normalization was carried out with the 484 
global mean method. Red pixels correspond to an increased abundance of miRNA in 485 
the urine samples, whereas green pixels indicate decreased mRNA levels. Rows 486 
represent individual miRNAs and columns represent experimental samples. (B) List of 487 
the differentially expressed miRNAs and their fold change values. 488 
Abbreviations: Pool=Pools of primers (Pool A and Pool B) for reverse transcription and 489 
preamplification (Applied Biosystems); p value=Student’s t test P values; FC=Fold change 490 
values were generated from the median expression of the miRNAs from the TaqMan® Human 491 
MicroRNA Array in the groups compared. FDR=False Discovery Rate. Statistical significance 492 
FDR<10%. 493 
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Figure 3. Kaplan-Meier curves for tumour progression and cancer-specific 495 
survival. (A) Kaplan-Meier estimates of probability of being free of tumour progression 496 
according to the identified model including miRNA-149 and miRNA-31 expression. Blue 497 
line represents low risk patients (RS<0.86; n=108), and red line high risk patients 498 
(RS≥0.86; n=39). (B) Kaplan-Meier estimates of probability of cancer-specific survival 499 
according to miRNA-149 expression. Blue line represents low risk patients (RS<0.93;  500 
n=96), and red line high risk patients (RS≥0.93; n=51). 501 
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 502 
TABLES AND THEIR LEGENDS 503 
 504 
Table 1. Pathological features of UTUC patients.  505 
 506 
    Hospital Clinic  Claude Huriez  Pitié Salpétrière  
Total (%) 
    of Barcelona  Hospital of Lille  Hospital of Paris  
N Total  78 56 16 150 (100) 
Histological Grade 
I 6 7 1 14 (9.3) 
II 34 11 3 48 (32) 
III 38 38 12 88 (58.7) 
Pathological Stage 
pTa 9 13 4 26 (17.3) 
pT1 20 17 5 42 (28) 
pT2 17 7 4 28 (18.7) 
pT3 18 17 3 38 (25.3) 
pT4 14 2 0 16 (10.7) 
507 
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 508 
Table 2. Technical validation of TaqMan Array data using LNA primers in the 509 
same cohort of patients (n=18). 510 
miRNA 
TaqMan Array (GM) LNA primers (miRNA-218) 
FC p value FC p value 
hsa-miR-141 -3.38 0.01* -1.37 0.26 
hsa-miR-149 -7.89 0.003* -5.02 0.06 
hsa-miR-181a-2* -2.88 0.03* -2.09 0.03* 
hsa-miR-200a -2.90 0.01* 1.06 0.77 
hsa-miR-31 -7.56 0.01* -2.16 0.45 
hsa-miR-378* -7.23 0.003* 4.47 0.05 
hsa-miR-493 4.42 0.006* 8.52 0.03* 
hsa-miR-99a 2.67 0.01* 3.12 0.01* 
Abbreviations: p value=Student’s t test P values; GM= global mean normalization method; 511 
miRNA-218=data normalization with miRNA-218; FC=Fold change. *Statistically significant 512 
(p<0.05).513 
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 514 
Table 3. Univariate analysis of predictors of tumour progression and cancer-515 
specific survival 516 
 517 
  TUMOUR PROGRESSION   CANCER SPECIFIC-SURVIVAL 
  HR 95% CI p value   HR 95% CI p value 
miR-149  0.77 0.66 - 0.90  0.0011*   0.80 0.68 - 0.94  0.0071*  
miR-181a.2 0.80 0.67 - 0.96  0.0139*  0.81 0.67 - 0.98 0.0337* 
miR-31  0.85 0.80 - 0.90 <0.0001*   0.96 0.88 -  1.05  0.3735  
miR-493 0.96 0.84 - 1.10 0.5516  0.93  0.81 - 1.06 0.2922  
miR-99a 0.97 0.83 - 1.13 0.6767  1.00  0.85 - 1.17  0.9844  
Pathological Stage 2.82 2.02 - 3.93 <0.0001*   1.88  1.39 -2.55 <0.0001*  
Histological Grade 3.52 1.70 - 7.31 0.0007*    2.29  1.25 - 4.21  0.0075 * 
 518 
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval. * Statistically significant 519 
(p<0.05).520 
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 521 
Table 4. Altered predicted KEGG pathways in tumour progression and cancer 522 
specific survival by miR-31 and miR-149. 523 
 524 
KEGG Pathway p value 
Progression   
T cell receptor signaling pathway -hsa04660  0.028 
B cell receptor signaling pathway -hsa04662  0.006 
GnRH signaling pathway -hsa04912  0.034 
ErbB signaling pathway -hsa04012 0.026 
Gap junction - hsa04540  0.033 
Epithelial cell signaling in Helicobacter pylori -hsa05120  0.008 
VEGF signaling pathway -hsa04370  0.000 
Adherens junction -hsa04520  0.013 
Survival   
Methane metabolism -hsa00680 0.000 
Heparan sulfate biosynthesis -hsa00534 0.029 
Vitamin B6 metabolism- hsa00750 0.038 
 525 
Abbreviations: KEGG, Kyoto Encyclopedia of Genes and Genomes; hsa value, KEGG 526 
reference of each pathway 527 
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